Serious skin reactions and selective COX-2 inhibitors: A case series from prescription-event monitoring in England

Drug Safety

Volumn 29, Issue 8, 2006, Pages 687-696

  Layton, Deborah ^a,b   Marshall, Vanessa ^a,b   Boshier, Andrew ^a,b   Friedmann, Peter ^c   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CITALOPRAM; CYCLOOXYGENASE 2 INHIBITOR; DIHYDROCODEINE; DOSULEPIN; ETHINYLESTRADIOL; ETORICOXIB; FOLIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; INDAPAMIDE; METHOTREXATE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; PYRIDOXINE; ROFECOXIB; SALAZOSULFAPYRIDINE; VALDECOXIB; WARFARIN; ZOPICLONE;

ADULT; AGED; ALLERGY; ANAMNESIS; ANEMIA; ANGIONEUROTIC EDEMA; APLASTIC ANEMIA; ARTICLE; BLISTER; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA EDEMA; CORNEA ULCER; DATA BASE; DISEASE SEVERITY; DRUG MONITORING; DRY SKIN; EOSINOPHILIA; ERYTHEMA; ERYTHEMA MULTIFORME; ERYTHRODERMA; EXFOLIATIVE DERMATITIS; FEMALE; FIXED DRUG ERUPTION; HEPATITIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERSENSITIVITY REACTION; JAUNDICE; LEUKOCYTOSIS; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LYMPHOCYTOSIS; MALE; MEDICAL INFORMATION; MEDICAL SPECIALIST; MOUTH ULCER; NEUTROPENIA; NEUTROPHILIA; OUTCOME ASSESSMENT; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PURPURA; QUESTIONNAIRE; RASH; RECTUM ULCER; RETROSPECTIVE STUDY; RISK FACTOR; RISK MANAGEMENT; SKIN MANIFESTATION; SKIN ULCER; STEVENS JOHNSON SYNDROME; STOMATITIS; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; UNITED KINGDOM; URTICARIA;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2 INHIBITORS; DRUG PRESCRIPTIONS; ENGLAND; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; INCIDENCE; LACTONES; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; PYRAZOLES; PYRIDINES; QUESTIONNAIRES; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SKIN; STEVENS-JOHNSON SYNDROME; SULFONAMIDES; SULFONES;

EID: 33746797625     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629080-00005     Document Type: Article

References (23)

1. Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005 Apr; 94 (4): 419-36
2. Glasser DL, Burroughs SH. Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy 2003 Apr; 23 (4): 551-3
3. Goldberg D, Panigrahi D, Barazi M, et al. A case of rofecoxib-associated Stevens-Johnson syndrome with corneal and conjunctival changes. Cornea 2004 Oct; 23 (7): 736-7
4. US Food and Drug Administration FDA Talk paper. FDA decision memo: analysis and recommendations for agency action: COX-2 selective and non-selective NSAIDs [online]. Available from URL: http://www.fda.gov/cder/drug/ infopage/COX2/default.html. [Accessed 2005 May 17]
5. US Food and Drug Administration. FDA Public Health Advisory. FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/COX2.htm. [Accessed 2005 May 17]
6. Pharmacia-Pfizer EEIG. BEXTRA SPC with changes highlighted as adopted by the CHMP on 15 December 2004. Doc ref: EMEA/204802/2004 [online]. Available from URL: http://www.emea.eu.int. [Accessed 2005 Feb 8]
7. Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005 Aug; 153 (2): 241-53
8. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 Oct 16; 282 (5388): 490-3
9. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003; 4 (8): 561-72
10. Shakir S. Prescription-event monitoring. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester, UK: John Wiley & Sons Ltd, 2005: 203-16
11. Council for International Organisations of Medical Sciences (CIOMS). Harmonizing the use of adverse-drug reaction terms: definitions of terms and minimum requirements for their use: respiratory disorders and skin disorders. Pharmacoepidemiol Drug Saf 1997 Mar; 6 (2): 115-27
12. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995 Dec 14; 333 (24): 1600-7
13. Shakir SAW. Causality and correlation in pharmacovigilance. In: Talbot J, Waller PC, editors. Stephens' detection of new adverse drug reactions. 5th ed. Chichester, UK: John Wiley & Sons Ltd, 2004: 329-43
14. Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf 2004; 27 (7): 477-87
15. Dunn N, Wilton L, Shakir S. Stevens-Johnson syndrome and antiepileptics. Lancet 1999 Sep 18; 354 (9183): 1033-4
16. Mockenhaupt M, Kelly JP, Kaufman D, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003 Oct; 30 (10): 2234-40
17. Stern RS, Albengres E, Carlson J, et al. An international comparison of case definition of severe adverse cutaneous reactions to medicines. Drug Saf 1993 Jan; 8 (1): 69-77
18. Strom B. Study designs available for pharmacoepidemiology studies. In: Strom B, editor. Pharmacoepidemiology. 3rd ed. Chichester, UK: John Wiley & Sons Ltd, 2000: 17-29
19. MHRA Adverse Drug Reactions Online Information Tracking Drug Analysis Print: Valdecoxib, June 2005 [online]. Available from URL: http://mhra.gov.uk. [Accessed 2006 Jun 2006]
20. MHRA Adverse Drug Reactions Online Information Tracking Drug Analysis Print: Celecoxib, June 2005 [online]. Available from URL: http://mhra.gov.uk. [Accessed 2006 Jun 2006]
21. MHRA Adverse Drug Reactions Online Information Tracking Drug Analysis Print: Rofecoxib, June 2005 [online]. Available from URL: http://mhra.gov.uk. [Accessed 2006 Jun 2006]
22. MHRA Adverse Drug Reactions Online Information Tracking Drug Analysis Print: Etoricoxib, June 2005 [online]. Available from URL: http://www.mhra.gov. uk. [Accessed 2006 Jun 2006]
23. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf 2005; 28 (10): 917-24